Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

NCT05398809 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
Alopecia Areata

Interventions

DRUG: Ruxolitinib

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)